Keyword Analysis & Research: imfinzi durvalumab
Keyword Research: People who searched imfinzi durvalumab also searched
Search Results related to imfinzi durvalumab on Search Engine
-
IMFINZI® (durvalumab) plus chemotherapy doubled overall …
https://www.astrazeneca-us.com:443/media/press-releases/2024/imfinzi-durvalumab-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial.html
WEB2 days ago · IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor's immune-evading tactics and …
DA: 57 PA: 84 MOZ Rank: 27
-
Immunotherapy for BTC, uHCC, NSCLC & ES-SCLC – IMFINZI® (durvalumab)
https://www.imfinzi.com:443/
WEBIMFINZI® (durvalumab) is an immunotherapy approved to treat patients with unresectable hepatocellular carcinoma, bile duct cancer, gallbladder cancer, unresectable Stage 3 NSCLC, Stage 4 NSCLC, and extensive-stage SCLC.
DA: 51 PA: 4 MOZ Rank: 27
-
What is IMFINZI® (durvalumab) – Treatment for Unresectable …
https://www.imfinzi.com:443/stage-3-nsclc/about/what-is-imfinzi.html
WEBIMFINZI ® (durvalumab) is the first immunotherapy treatment approved for adults living with unresectable Stage 3 non-small cell lung cancer (NSCLC) whose disease has not progressed after CRT. CRT is a combination of chemotherapy and radiation given at …
DA: 54 PA: 91 MOZ Rank: 22
-
IMFINZI® (durvalumab) significantly improved overall survival and
https://www.astrazeneca-us.com:443/media/press-releases/2024/imfinzi-significantly-improved-overall-survival-and-progression-free-survival-for-patients-with-limited-stage-small-cell-lung-cancer-in-adriatic-phase-III-trial.html
WEBApr 5, 2024 · IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial. PUBLISHED 5 April 2024. First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial.
DA: 57 PA: 59 MOZ Rank: 54
-
What is IMFINZI® (durvalumab) – Treatment for ES-SCLC
https://www.imfinzi.com:443/small-cell-lung-cancer/about/what-is-imfinzi.html
WEBIMFINZI ® (durvalumab) is a prescription medicine that works with the immune system to help the body fight cancer. It is used to treat extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy. IMFINZI may also attack healthy cells. WHAT’S THE NEXT STEP?
DA: 70 PA: 11 MOZ Rank: 8
-
Imfinzi plus chemotherapy doubled overall survival rate at three …
https://www.astrazeneca.com:443/media-centre/press-releases/2024/imfinzi-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial.html
WEB2 days ago · Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).. These results from TOPAZ-1, …
DA: 82 PA: 39 MOZ Rank: 73
-
Durvalumab - Wikipedia
https://en.wikipedia.org:443/wiki/Durvalumab
WEBDurvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ) with the PD-1 (CD279).
DA: 54 PA: 1 MOZ Rank: 26
-
Imfinzi: Uses, Dosage, Side Effects & Warnings - Drugs.com
https://www.drugs.com:443/imfinzi.html
WEBJun 2, 2023 · Imfinzi (durvalumab) is a cancer medicine that works with your immune system to interfere with the growth and spread of cancer cells in the body. Imfinzi is used to treat non-small cell lung cancer (NSCLC), small cell lung cancer, or biliary tract cancer.
DA: 72 PA: 31 MOZ Rank: 15
-
Durvalumab (Imfinzi) | Cancer information | Cancer Research UK
https://www.cancerresearchuk.org:443/about-cancer/treatment/drugs/durvalumab
WEBPICC line. portacath. If you don't have a central line. You might have treatment through a thin short tube (a cannula) that goes into a vein in your arm. You have a new cannula each time you have treatment. How often do you have durvalumab? You have durvalumab as cycles of treatment.
DA: 26 PA: 73 MOZ Rank: 100
-
Imfinzi | European Medicines Agency
https://www.ema.europa.eu:443/en/medicines/human/EPAR/imfinzi
WEBImfinzi contains the active substance durvalumab. How is Imfinzi used? How does Imfinzi work? What benefits of Imfinzi have been shown in studies? What are the risks associated with Imfinzi? Why is Imfinzi authorised in the EU? What measures are being taken to ensure the safe and effective use of Imfinzi? Other information about Imfinzi.
DA: 44 PA: 84 MOZ Rank: 52